[Respiratory failure and pulmonary fibrosis as a late side-effect after chemotherapy-induced by oxygen administration].
Pulmonary fibrosis (PF) may develop following successful chemotherapy for malignancy, even if such therapy is not combined with radiotherapy. Bleomycin, which is known to induce acute pneumonitis and lung fibrosis, is especially associated with chemotherapy-induced PF, and bleomycin-induced pulmonary fibrosis can occur more than five years after such therapy. Additionally, supplemental oxygen therapy can trigger the onset of pneumonitis and lethal PF in patients who have previously received bleomycin therapy. Careful assessment of lung function via spiroergometry and arterial blood gas analysis during exercise are required if the administration of supplemental oxygen is considered. Two case reports reveal the potential lethal risk of oxygen for patients who have been treated with bleomycin: (1) a patient with successfully resected and treated basal tongue carcinoma and (2) a patient in remission after being treated for non-Hodgkin lymphoma. Single and double lung transplantation is the only therapeutic option for patients with severe, oxygen-induced PF and should be included as an indication for lung transplantation. Early recognition of pulmonary diffusion abnormalities and establishing a risk profile, as well as consequent monitoring of pulmonary function, may help to avoid or at least reduce the risk of PF induced by oxygen therapy when administered to patients who have previously been given bleomycin.
Grahmann
P R
PR
Friedrich-Schiller-Universität Jena, Klinik für Innere Medizin I, Kardiologie, Angiologie, Intensivmedizin, Pneumologie und Allergologie/Immunologie. pr.grahmann@med.uni-jena.de
Brauer
M
M
Hüter
L
L
Sayer
H
H
Neumann
R
R
Braun
R K
RK
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D001784:Blood Gas Analysis; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D016040:Lung Transplantation; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000517:prevention & control; D012129:Respiratory Function Tests; D012131:Respiratory Insufficiency / Q000139:chemically induced* / Q000517:prevention & control
D001761:Bleomycin